# US 2001/0012632 A1 · Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0012632 A1
- Document ID: US20010012632A1
- Status: Published application
- Kind: A1
- Application number: 09/802,397
- Filed: 2001-03-09
- Published: 2001-08-09
- Earliest claimed: 1995-03-31
- Inventors: Muriel Moser; Oberdan Leo; Laurence Lespagnard; Jacques Urbain; Catherine Bruyns; Catherine Gerard; Michel Goldman; Thierry Velu; Fabienne Willems; Nicole Tasiaux; Jason Perret; AnneMarie Verheyden
- Web page: https://patentgrep.com/patent/US20010012632A1

## CPC

- C12N 5/16: Animal cells
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/35: Cytokines
- A61K 40/42: Cancer antigens
- A61K 2239/31: characterized by the route of administration
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method produces an anti-tumor response in a mammalian subject in need of anti-tumor treatment. Hybrids of tumor cells with dendritic cells or dendritic-like cells can be administered to the subject. The tumor cell of the hybrid corresponds to the tumor of the subject. Alternatively, autologous immune cells of the subject can be administered in which the immune cells are activated in vitro by co-cultivation with these hybrids.

## Claims

### Claim 1

A method for producing an anti-tumor response in a mammalian subject in need of anti-tumor treatment, said method comprising administering to said subject a plurality of dendritic cell/tumor cell hybrids wherein said tumor cell corresponds to the tumor cell in said hybrids.

### Claim 2 (depends on 1)

A method for producing an anti-tumor response in a mammalian subject in need of anti-tumor treatment, said method comprising administering to said subject autologous immune cells activated in vitro by the method of claim 1.

### Claim 3

A method for producing an anti-tumor response in a mammalian subject in need of anti-tumor treatment, said method comprising administering to said subject a dendritic-like cell or dentritic cell/tumor cell hybridoma, wherein said tumor cell corresponds to the tumor cell in said mammalian subject.

### Claim 4

A method for producing an anti-tumor response in a mammalian subject in need of anti-tumor treatment, said method comprising administering to said subject autologous immune cells activated in vitro by co-cultivating in vitro a dendritic cell/tumor cell hybridoma with immune cells from a mammalian subject in need of anti-tumor treatment.
